“Our outlook is that as evidence grows and we find new ways and also different plan designs are available to different employers that, that will continue.”

In context

“nes over the next 6 months or so for January of '26? Michael Czapar: Great. Thanks, Dave, for the question. We'll go to Ilya to talk about the progress in the Zepbound employer coverage opt-in. Ilya Yuffa: Sure. Thanks for the question, Dave. As we take a look at employer coverage, it's important for us to grow coverage over time. What we've seen in different offerings across the different plans, and some are more complex than others, and we've seen an increase overall, but it has been steady around 50% to 55% employer opt-in coverage. At the same time, we are seeing new benefit designs, like, for instance, Evernorth, a cap on out-of-pocket for employees that make the prior authorization simplified, and that may grow employer opt-ins over time. That's something that we're working through. Our outlook is that as evidence grows and we find new ways and also different plan designs are available to different employers that, that will continue. Operator: The next question will be from Terence Flynn from Morgan Stanley. Terence C. Flynn: Congrats on all the progress. Just wondering on orforglipron in light of the ATTAIN-1 data, if you can just frame expectations for us down for the upcoming ATTAIN-2 Phase III data. And then any early insights into the potential CMMI obesity, Medicare/Medicaid pilot that I think we saw some press reports about? Michael Czapar: For that we'll go to Ken to answer the question on expectations for ATTAIN-2. Kenneth L. Custer: Thanks, Terence, for the question on ATTAIN-2. We're very pleased with what we disclosed this morning in ATTAIN-1, which is our first Phase III study in obesity without diabetes. And of course, we had a great result with ACHIEVE-1 in patients with diabetes. So as we look ahead to”